The first patient has been enrolled in a prospective, randomized, multicenter study of the iTrack Advance canaloplasty device, according to a press release from Nova Eye Medical.
The CATALYST study will assess the effectiveness, safety and quality of life outcomes of canaloplasty procedures conducted with the device. Up to 80 participants with mild to moderate uncontrolled open-angle glaucoma, who are on between one and four medications, will be enrolled across five sites in Germany.
“The major advantage of this new device for the surgeon is that it allows canaloplasty to (Read more...)